Vertex Pharmaceuticals Stock Analysis

VRTX Stock  USD 419.63  1.01  0.24%   
Vertex Pharmaceuticals is overvalued with Real Value of 335.7 and Target Price of 388.67. The main objective of Vertex Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Vertex Pharmaceuticals is worth, separate from its market price. There are two main types of Vertex Pharmaceuticals' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Vertex Pharmaceuticals' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Vertex Pharmaceuticals' stock to identify patterns and trends that may indicate its future price movements.
The Vertex Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Vertex Pharmaceuticals is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Vertex Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Vertex Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Vertex Stock Analysis Notes

About 96.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.57. Vertex Pharmaceuticals recorded earning per share (EPS) of 13.89. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 24th of August 2000. Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 00 people. For more information please call MD FASN at 617 341 6100 or visit https://www.vrtx.com.

Vertex Pharmaceuticals Quarterly Total Revenue

2.52 Billion

Vertex Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Vertex Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Vertex Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Vertex Pharmaceuticals is unlikely to experience financial distress in the next 2 years
Over 96.0% of the company outstanding shares are owned by institutional investors
Latest headline from arstechnica.com: Google goes open AI with Gemma, a free, open-weights chatbot family

Vertex Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Vertex Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vertex Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
5th of February 2024
Upcoming Quarterly Report
View
6th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Vertex Largest EPS Surprises

Earnings surprises can significantly impact Vertex Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2013-01-29
2012-12-31-0.08-0.09-0.0112 
2016-10-25
2016-09-300.180.16-0.0211 
2000-02-16
1999-12-310.010.030.02200 
View All Earnings Estimates

Vertex Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Vertex Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Vertex Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Vertex Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
13th of February 2024
Unclassified Corporate Event
View
9th of February 2024
Unclassified Corporate Event
View
5th of February 2024
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
25th of January 2024
Unclassified Corporate Event
View
8th of December 2023
Other Events
View
5th of December 2023
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
6th of November 2023
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
5th of October 2023
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View

Vertex Pharmaceuticals Thematic Classifications

In addition to having Vertex Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products Idea
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Vertex Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Vertex Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vertex Pharmaceuticals backward and forwards among themselves. Vertex Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Vertex Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Massachusetts Financial Services Company2023-12-31
3.6 M
Capital Research Global Investors2023-12-31
3.6 M
Loomis, Sayles & Company Lp2023-09-30
3.2 M
Norges Bank2023-12-31
M
Clearbridge Advisors, Llc2023-09-30
2.9 M
Ameriprise Financial Inc2023-09-30
2.9 M
Morgan Stanley - Brokerage Accounts2023-09-30
2.9 M
Northern Trust Corp2023-09-30
2.8 M
Ubs Asset Mgmt Americas Inc2023-12-31
2.6 M
Blackrock Inc2023-09-30
22.6 M
Vanguard Group Inc2023-09-30
22 M
Note, although Vertex Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Vertex Market Capitalization

The company currently falls under 'Mega-Cap' category with a current market capitalization of 108.65 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vertex Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Vertex Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Vertex Profitablity

Vertex Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Vertex Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Vertex Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Vertex Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Vertex Pharmaceuticals' profitability requires more research than a typical breakdown of Vertex Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.37 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.38 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.38.
Last ReportedProjected for 2024
Return on Investment 31.07  33.52 
Return on Average Assets 0.17  0.19 
Return on Average Equity 0.23  0.25 
Return on Invested Capital 0.70  0.56 
Return on Sales 0.45  0.48 

Management Efficiency

Vertex Pharmaceuticals has return on total asset (ROA) of 0.1317 % which means that it generated a profit of $0.1317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2299 %, meaning that it created $0.2299 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Vertex Pharmaceuticals' Return on Investment is fairly stable as compared to the past year. Return on Average Assets is likely to rise to 0.19 in 2024, whereas Return on Invested Capital is likely to drop 0.56 in 2024. At this time, Vertex Pharmaceuticals' Total Assets are fairly stable as compared to the past year. Current Assets is likely to rise to about 15.3 B in 2024, whereas Tax Assets are likely to drop slightly above 1.6 B in 2024.
Last ReportedProjected for 2024
Book Value per Share 68.22  73.61 
Enterprise Value over EBIT 21.00  22.66 
Enterprise Value over EBITDA 20.52  30.26 
Price to Book Value 5.96  8.86 
Tangible Assets Book Value per Share 80.72  87.10 
Enterprise Value94.5 B75.7 B
Tangible Asset Value20.8 B22.4 B
The analysis of Vertex Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Vertex Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Vertex Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
0.362

Technical Drivers

As of the 22nd of February, Vertex Pharmaceuticals has the Risk Adjusted Performance of 0.1009, semi deviation of 0.9817, and Coefficient Of Variation of 666.29. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vertex Pharmaceuticals, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Vertex Pharmaceuticals, which can be compared to its competition. Please validate Vertex Pharmaceuticals value at risk, as well as the relationship between the semi variance and kurtosis to decide if Vertex Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 419.63 per share. Given that Vertex Pharmaceuticals has jensen alpha of 0.1218, we advise you to double-check Vertex Pharmaceuticals's current market performance to make sure the company can sustain itself at a future point.

Vertex Pharmaceuticals Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Vertex Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Vertex Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
.

Vertex Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vertex Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vertex Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vertex Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Vertex Pharmaceuticals Predictive Daily Indicators

Vertex Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vertex Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Vertex Pharmaceuticals Forecast Models

Vertex Pharmaceuticals' time-series forecasting models are one of many Vertex Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vertex Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Vertex Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Vertex Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Vertex shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Vertex Pharmaceuticals. By using and applying Vertex Stock analysis, traders can create a robust methodology for identifying Vertex entry and exit points for their positions.
Last ReportedProjected for 2024
Operating Margin 43.41  46.84 
EBITDA Margin 0.47  0.50 
Gross Margin 0.87  0.83 
Profit Margin 0.37  0.40 

Current Vertex Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vertex analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Vertex analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
388.67Buy31Odds
Vertex Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Vertex analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Vertex stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Vertex Pharmaceuticals, talking to its executives and customers, or listening to Vertex conference calls.
Vertex Analyst Advice Details

Vertex Stock Analysis Indicators

Vertex Pharmaceuticals stock analysis indicators help investors evaluate how Vertex Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Vertex Pharmaceuticals shares will generate the highest return on investment. By understating and applying Vertex Pharmaceuticals stock analysis, traders can identify Vertex Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow9.2 B
Common Stock Shares Outstanding257.7 M
Total Stockholder Equity17.6 B
Tax Provision760.2 M
Quarterly Earnings Growth Y O Y0.181
Property Plant And Equipment Net1.5 B
Cash10.4 B
Accounts Payable364.9 M
50 Day M A415.6026
Total Current Liabilities3.5 B
Non Current Assets Total8.6 B
Forward Price Earnings25.8398
Non Currrent Assets Other895.3 M
Stock Based Compensation484.1 M
When determining whether Vertex Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vertex Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vertex Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vertex Pharmaceuticals Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Complementary Tools for Vertex Stock analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.181
Earnings Share
13.89
Revenue Per Share
38.297
Quarterly Revenue Growth
0.093
Return On Assets
0.1317
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.